|SERES THERAPEUTICS, INC. filed this Form 8-K on 10/16/2017|
PRECLINICAL PHASE 1b PHASE 2
Synthetically fermented Infectious Inflammatory SER-301 Inflammatory Bowel Disease (IBD) SER-262 Primary C. difficile Top line SER-287 Phase 1b data disclosed in October 2, 2017 press
release; Collaboration with Nestlé Health Science regarding
C. difficile and IBD programs for markets only outside of North America SER-155 Prevention of infection and GVHD following hematopoietic stem cell or solid organ transplant Biologically sourced SER-287 Ulcerative colitis PHASE 3 SER-109
Recurrent C. difficile Research Collaborations CLINICAL PROGRAMS Positive top-line Phase 1b results Robust microbiome therapeutics pipeline
© Seres Therapeutics. All Rights Reserved.